Loading…
Curex was warned for unlawfully selling unapproved and misbranded compounded drugs (semaglutide and tirzepatide) over the internet to U.S. consumers. The company made false or misleading claims on its website, including stating its products were "clinically proven" and "the same active ingredients as" FDA-approved products like Ozempic, Mounjaro, and Zepbound, when in fact compounded drugs are not FDA-approved. These misleading claims violated the Federal Food, Drug, and Cosmetic Act by misbranding the products under sections 502(a) and 502(bb), and constituted prohibited introduction of misbranded drugs into interstate commerce under section 301(a).